Antimalarial drug resistance in Africa: Key lessons for the future

Annals of the New York Academy of Sciences

Volumn 1342, Issue 1, 2015, Pages 62-67

  Takala Harrison, Shannon ^a   Laufer, Miriam K ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Africa; Artemisinin resistance; Artemisinin based combination therapy; Drug resistance; Malaria; Molecular epidemiology

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ARTEMISININ DERIVATIVE; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PYRIMETHAMINE; SULFADOXINE;

AFRICA; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASIA; CLINICAL STUDY; GENOMICS; HUMAN; MALAWI; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FORECASTING; MALARIA; PHYSIOLOGY;

AFRICA; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; MALARIA; PYRIMETHAMINE; SULFADOXINE;

EID: 84927799735     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12766     Document Type: Article

References (44)

1. Mu, J., R.A. Myers, H. Jiang, et al. 2010. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat. Genet. 42: 268-271.
2. Takala-Harrison, S., T.G. Clark, C.G. Jacob, et al. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. U. S. A. 110: 240-245.
3. Takala-Harrison, S., C.G. Jacob, C. Arze, et al. 2015. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211: 670-679.
4. Cheeseman, I.H., B.A. Miller, S. Nair, et al. 2012. A major genome region underlying artemisinin resistance in malaria. Science 336: 79-82.
5. Sullivan, D.J., Jr., I.Y. Gluzman, D.G. Russell & D.E. Goldberg. 1996. On the molecular mechanism of chloroquine's antimalarial action. Proc. Natl. Acad. Sci. U. S. A. 93: 11865-11870.
6. Fidock, D.A., T. Nomura, A.K. Talley, et al. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6: 861-871.
7. Djimde, A., O.K. Doumbo, J.F. Cortese, et al. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344: 257-263.
8. Wootton, J.C., X. Feng, M.T. Ferdig, et al. 2002. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418: 320-323.
9. Muhamad, P., P. Phompradit, W. Sornjai, et al. 2011. Polymorphisms of molecular markers of antimalarial drug resistance and relationship with artesunate-mefloquine combination therapy in patients with uncomplicated Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 85: 568-572.
10. Phompradit, P., P. Muhamad, R. Wisedpanichkij, et al. 2014. Four years' monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border. Malar. J. 13: 23.
11. Griffing, S., L. Syphard, S. Sridaran, et al. 2010. pfmdr1 amplification and fixation of pfcrt chloroquine resistance alleles in Plasmodium falciparum in Venezuela. Antimicrob. Agents Chemother. 54: 1572-1579.
12. Bacon, D.J., A.M. McCollum, S.M. Griffing, et al. 2009. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob. Agents Chemother. 53: 2042-2051.
13. Kublin, J.G., J.F. Cortese, E.M. Njunju, et al. 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J. Infect. Dis. 187: 1870-1875.
14. Frosch, A.E., M.K. Laufer, D.P. Mathanga, et al. 2014. Return of widespread chloroquine-sensitive Plasmodium falciparum to Malawi. J. Infect. Dis. 210: 1110-1114.
15. Laufer, M.K., P.C. Thesing, N.D. Eddington, et al. 2006. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355: 1959-1966.
16. Laufer, M.K., P.C. Thesing, F.K. Dzinjalamala, et al. 2012. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS ONE 7: e42284.
17. Laufer, M.K., S. Takala-Harrison, F.K. Dzinjalamala, et al. 2010. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J. Infect. Dis. 202: 801-808.
18. Basco, L.K., P. Eldin de Pécoulas, C.M. Wilson, et al. 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69: 135-138.
19. Plowe, C.V., A. Djimde, M. Bouare, et al. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 52: 565-568.
20. Roper, C., R. Pearce, B. Bredenkamp, et al. 2003. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 361: 1174-1181.
21. Mita, T., M. Venkatesan, J. Ohashi, et al. 2011. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J. Infect. Dis. 204: 1980-1988.
22. McCollum, A.M., K. Mueller, L. Villegas, et al. 2007. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob. Agents Chemother. 51: 2085-2091.
23. Gesase, S., R.D. Gosling, R. Hashim, et al. 2009. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 4: e4569.
24. Artimovich, E., K. Schneider, T.E. Taylor, et al. 2015. Persistence of sulfadoxine-pyrimethamine resistance despite reduction of drug pressure in Malawi. J. Infect. Dis. pii: jiv078.
25. Thera, M.A., P.S. Sehdev, D. Coulibaly, et al. 2005. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis. 192: 1823-1829.
26. Gasasira, A.F., M.R. Kamya, E.O. Ochong, et al. 2010. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar. J. 9: 177.
27. Iriemenam, N.C., M. Shah, W. Gatei, et al. 2012. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar. J. 11: 134.
28. Frosch, A.E., M. Venkatesan, M.K. Laufer. 2011. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar. J. 10: 116.
29. Salissou, A., H. Zamanka, B.B. Biyghe, et al. 2014. Low prevalence of Pfcrt resistance alleles among patients with uncomplicated Falciparum malaria in Niger six years after chloroquine withdrawal. Malar. Res. Treat. 2014: 614190.
30. Mbogo, G.W., S. Nankoberanyi, S. Tukwasibwe, et al. 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am. J. Trop. Med. Hyg. 91: 54-61.
31. Wurtz, N., B. Fall, A. Pascual, et al. 2012. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar. J. 11: 197.
32. Antonia, A.L., S.M. Taylor, M. Janko, et al. 2014. A cross-sectional survey of Plasmodium falciparum pfcrt mutant haplotypes in the Democratic Republic of Congo. Am. J. Trop. Med. Hyg. 90: 1094-1097.
33. Venkatesan, M., N.B. Gadalla, K. Stepniewska, et al. 2014. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am. J. Trop. Med. Hyg. 91: 833-843.
34. Dondorp, A.M., F. Nosten, P. Yi, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361: 455-467.
35. Noedl, H., Y. Se, K. Schaecher, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359: 2619-2620.
36. Kyaw, M.P., M.H. Nyunt, K. Chit, et al. 2013. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE 8: e57689.
37. Phyo, A.P., S. Nkhoma, K. Stepniewska, et al. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379: 1960-1966.
38. Ariey, F., B. Witkowski, C. Amaratunga, et al. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505: 50-55.
39. Straimer, J., N.F. Gnädig, B. Witkowski, et al. 2015. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347: 428-431.
40. Ashley, E.A., M. Dhorda, R.M. Fairhurst, et al. 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371: 411-423.
41. Maiga, A.W., B. Fofana, I. Sagara, et al. 2012. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 87: 23-28.
42. Borrmann, S., P. Sasi, L. Mwai, et al. 2011. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS ONE 6: e26005.
43. Taylor, S.M., C.M. Parobek, D.K. DeConti, et al. 2015. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J. Infect. Dis. 211: 680-688.
44. Kamau, E., S. Campino, L. Amenga-Etego, et al. 2015. K13-propeller polymorphisms in Plasmodium falciparum parasites from Sub-Saharan Africa. J. Infect. Dis. 211: 1352-1355.